Survey: Biosimilars are Gaining Momentum Among Payers

FormularyWatch, Tasmina Hydery and Jennifer Snow

Managed care organizations are anticipating pharmacy benefit plans to include preferred biosimilars and negotiate rebates/contracts, but legal and regulatory hurdles still exist, finds a survey of 51 payers conducted by AmerisourceBergen/Xcenda. The results were presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting in Denver, Oct. 18-21, 2021.

“About 59% of those we surveyed said they agreed that biosimilars have provided their organization with meaningful savings. We have another 35% of people say they somewhat agree with that statement,” Tasmina Hydery, Pharm.D., assistant director in integrated technology solutions at AmerisouceBergen/Xcenda, said in an interview with FormularyWatch.

For the full article, visit FormularyWatch.